Inhibition of Tissue Activator by Urokinase Inhibitor

T Kawano; Y Uemura

doi:10.1055/s-0038-1654286

Thrombosis and Haemostasis, Inhaltsverzeichnis

Thromb Haemost 1971; 25(01): 129-133
DOI: 10.1055/s-0038-1654286

Originalarbeiten – Original Articles – Travaux Originaux

Schattauer GmbH

Inhibition of Tissue Activator by Urokinase Inhibitor

T Kawano

¹Plasma Fractionation Department, The Green Cross Corporation, Joto-ku, Osaka

,

Y Uemura

¹Plasma Fractionation Department, The Green Cross Corporation, Joto-ku, Osaka

› Institutsangaben

Abstract

Summary

Inhibition of tissue activator purified from human heart by urokinase inhibitor purified from human placenta was observed by both the fibrin plate method and fibrin clot lysis time method. It was shown to be of much less on extent in comparison with urokinase, that is, 20 Ploug units of urokinase were completely inhibited by approximately 100 or 200 u of urokinase inhibitor in the respective methods but 6 Ploug units of tissue activator were inhibited only 25% to 50% even though 1,000 u of urokinase inhibitor were used.

Volltext

Referenzen

References
1 Alkjaersig N, Fletcher A. P, Sherry S. Epsilon-Aminocaproic Acid: an Inhibitor of Plasminogen Activation. J. biol. Chem 234: 832 1959;
2 Bachmann F, Fletcher A. P, Alkjaersig N, Sherry S. Partial Purification and Properties of the Plasminogen Activator from Pig Heart. Biochemistry 03: 1578 1964;
3 Bernik M. B, Kwaan H. C. Plasminogen Activator Activity in Cultures from Human Tissues. An Immunological and Histochemical Study. J. clin. Invest 48: 1740 1969;
4 Blombäck B, Blombäck M. Purification of Human and Bovine Fibrinogen. Arkiv Kemi 10: 415 1957;
5 Brahman P, Astrup T. Selective Inhibition in Human Pregnancy Blood of Urokinase Induced Fibrinolysis. Scand. J. clin. Lab. Invest 15: 603 1963;
6 Dudok de Wit C. hr. Investigations on the Inhibitors of the Fibrinolytic System. Thrombos. Diathes. haemorrh. (Stuttg) 12: 105 1964;
7 Januszko T, Buluk K, Uszynska-Folejewska R, Uszynski M. Measurement of the Inhibitor of Plasminogen Activation in the Euglobulin Test. Polish med. J 05: 914 1966;
8 Kawano T, Morimoto K, Uemura Y. Urokinase Inhibitor in Human Placenta. Nature 217: 253 1968;
9 Kawano T, Morimoto K, Uemura Y. Partial Purification and Properties of Urokinase Inhibitor from Human Placenta. J. Biochem 67: 333 1970;
10 Kok P, Astrup T. Isolation and Purification of a Tissue Plasminogen Activator and Its Comparison with Urokinase. Biochemistry 08: 79 1969;
11 Kucinski G. S, Fletcher A. P, Sherry S. Effect of Urokinase Antiserum on Plasminogen Activators: Demonstration of Immunologic Dissimilarity between Plasma Plasminogen Activator and Urokinase. J. clin. Invest 47: 1238 1968;
12 Lauritsen O. S. Urokinase Inhibitor in Human Plasma. Scand. J. clin. Lab. Invest 22: 314 1968;
13 Lauritsen O. S. The Fibrinolytic Enzyme System of Human Blood Plasma in Pregnancy. Scand. J. clin. Lab. Invest 23: 191 1969;
14 Miller K. D, Copeland W. H. Isolation of Human Thrombin. Proc. Soc. exp. Biol. (N. Y.) 111: 512 1962;
15 Ploug J, Kjeldgaard N. O. Urokinase. An Activator of Plasminogen from Human Urine. I. Isolation and Properties. Biochim. biophys. Acta (Amst) 24: 278 1957;
16 Thorsen S, Astrup T. Biphasic Inhibition of Urokinase. Induced Fibrinolysis by Epsilon Aminocaproic Acid; Distinction from Tissue Plasminogen Activator. Proc. Soc. exp. Biol. (N. Y.) 130: 811 1969;
17 Uszynski M, Uszynski-Folejewska R. Plasminogen Activator and Urokinase Inhibitor in Myometrium, Placenta, and Amniotic Fluid. Amer. J. Obst. Gynec 105: 1041 1969;